Summary of COVID-19 emvododstat studies

1. Ngumah et al., Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)

189 patient emvododstat late treatment RCT: 132% higher mortality (p=0.16) and 47% higher ventilation (p=0.31).
RCT 189 hospitalized patients showing higher mortality with emvododstat (PTC299), without statistical significance.
Jun 2023, NCT04439071, https://clinicaltrials.gov/study/NCT04439071, https://c19p.org/ngumah